There is a disease that has been causing heart failure in elderly people, probably for as long as humans have been getting old, and for most of that time it was found only at autopsy. The heart muscle would be full of a waxy material. The pathologist would note it. Then the patient would be buried and the finding would not help anyone.
In the last decade, this disease went from a footnote in pathology reports to something cardiologists are actively screening for. The reason is a simple nuclear imaging scan that turned out to be highly specific for the condition. Once there was a way to find it without cutting someone open, clinicians started looking. And once they started looking, they found it everywhere.
The condition is called transthyretin amyloid cardiomyopathy, usually abbreviated ATTR-CM. This week, in Nature Medicine, a paper was published on combining two different drugs that work through completely different mechanisms to fight it. To understand why that combination matters and what the paper found, you need to understand the disease from the protein up.
Transthyretin is a protein the liver makes. It has a job: carrying thyroid hormone and a form of vitamin A through the bloodstream to the tissues that need them. To do that job, four copies of the protein assemble together into a cluster. That cluster is the working form of the protein.
The cluster can fall apart. Under certain conditions, the four units come apart into individual pieces. And individual pieces of transthyretin, freed from the cluster, can change shape. They misfold. When proteins misfold, they do something problematic: they have a tendency to stick to other misfolded proteins and form long fibers. Those fibers accumulate in organs. The word for this kind of fiber accumulation is amyloid. The word for the disease caused by it is amyloidosis.
In transthyretin amyloidosis, the heart is the primary target. Amyloid fibers deposit in the walls of the heart muscle, and the result is stiffness. A stiff heart cannot relax properly between beats. A heart that cannot relax cannot fill with blood properly. When it then contracts, it is squeezing a chamber that was not fully loaded, and less blood goes out with each heartbeat. This is a form of heart failure called restrictive cardiomyopathy.
What does daily life look like when you have ATTR cardiomyopathy? In the early stages, it is easy to attribute the symptoms to aging. You get winded climbing stairs when you did not before. Walking fast is harder. You feel tired in the afternoon in a way that seems unusual. The legs swell a little by the end of the day and feel heavy.
Because the disease predominantly affects men over seventy, those symptoms often get attributed to age, to deconditioning, to being out of shape. The patient and the doctor both accept the explanation and move on. The diagnosis is not made. The disease progresses quietly.
As it advances, the symptoms become harder to explain away. Exercise tolerance drops further. The legs swell more noticeably. Fluid accumulates in the abdomen in some patients. Breathlessness at rest becomes a problem. Hospital admissions for heart failure become part of life. Each hospitalization involves diuretics to clear the fluid, some recovery, and then a return to a trajectory that is slowly declining.
The symptoms look like any other heart failure from the outside. Shortness of breath when you exert yourself. Fatigue that seems disproportionate to activity. Legs and ankles that swell with fluid. If you show up at a hospital with those symptoms and the doctor does an echocardiogram, the most common result is that the heart looks like it is pumping normally. The ejection fraction, the measure of how much blood the heart squeezes out with each beat, is preserved. The heart is not weakened in the way most people picture heart failure. It is stiff. It cannot fill.
This is called heart failure with preserved ejection fraction. It is different from the more commonly pictured form of heart failure, where the heart is weakened and enlarged and the ejection fraction is reduced. That distinction matters enormously for treatment, because most of the well-established heart failure medications, the drugs with decades of evidence, work by addressing a weakened pumping function. In heart failure caused by a stiff heart that cannot fill, those same drugs are largely ineffective or can be harmful. A patient treated for the wrong kind of heart failure gets drugs that do not help and misses the one that could.
There are two forms of this disease, and they are worth distinguishing.
The hereditary form runs in families. It is caused by mutations in the gene that codes for transthyretin. Certain mutations make the protein especially prone to coming apart from its four-unit cluster, which means more individual pieces circulating, more misfolding, more fiber accumulation. The hereditary form can cause cardiomyopathy but also neurological disease, because transthyretin deposits also occur in peripheral nerves. It tends to present at earlier ages than the other form.
The wild-type form, which was once called senile cardiac amyloidosis, involves the normal non-mutant protein. The ordinary protein is not perfectly stable forever. Over decades of a human life, in some people, it starts to come apart and misfold at a rate that causes meaningful accumulation in the heart. Wild-type ATTR amyloidosis is predominantly a disease of men over seventy. For decades it was thought to be rare because it was rarely found before death. It is now recognized as a common cause of unexplained heart failure in older men, with prevalence estimates that are much higher than the medical community appreciated ten years ago.
Why was it missed for so long? Two reasons.
First, the diagnosis required a biopsy. To confirm amyloid deposits in the heart, you needed tissue. Getting tissue from the heart is an invasive procedure. You do not do that routinely in an elderly man with heart failure. You treat the heart failure and move on.
Second, there was nothing to offer even if you found it. For most of the history of this disease, treatment was supportive: diuretics to clear the fluid, careful management of heart rate, avoiding medications that worsen the physiology. No treatment that addressed the underlying cause. If the diagnosis does not change what you do, the incentive to pursue it is low.
And there was a practical incentive problem. Diagnosing a disease for which there is no treatment does not change patient care. It adds information, potentially distressing information, without offering anything actionable. Many clinicians, consciously or not, do not pursue diagnoses that will not change their management. When the diagnosis is made only by biopsy and there is nothing to offer, the incentive to pursue that biopsy is low. The disease goes undiagnosed not because physicians are incompetent but because the system of incentives and available tools did not support finding it.
Both of those things changed.
The imaging test that changed diagnosis is a nuclear scan using a tracer called technetium pyrophosphate. This tracer was originally developed for bone imaging. It was noticed, somewhat by accident, that it also lights up transthyretin amyloid deposits in the heart with high sensitivity and specificity. You can now make the diagnosis of ATTR cardiomyopathy non-invasively, without a biopsy, with a scan that takes about an hour in a nuclear medicine department. Diagnosis rates rose dramatically once this became widely known.
The treatment that changed the other half of the equation was tafamidis, approved in 2019 based on a randomized trial called ATTR-ACT. That trial showed that tafamidis reduced mortality and hospitalizations compared to placebo over thirty months. It became the first disease-modifying treatment for ATTR cardiomyopathy.
Tafamidis works by stabilizing the four-unit cluster of transthyretin. The protein normally exists in that cluster form, and the problem begins when the cluster falls apart. Tafamidis binds to the cluster at a specific site and holds the four units together. The cluster is less likely to come apart. Fewer individual pieces circulate. Less misfolding. Less fiber formation. Slower accumulation of amyloid in the heart.
Think of it as a chemical fastener holding a structure together. The structure wants to fall apart under certain conditions. The fastener keeps it intact. You are not changing what the protein does. You are preventing the first step in the chain that leads to disease.
The ATTR-ACT trial that established tafamidis enrolled around four hundred patients, divided between those with hereditary and wild-type ATTR cardiomyopathy. The trial ran for thirty months. Compared to placebo, tafamidis reduced all-cause mortality and cardiovascular hospitalizations. It also slowed the decline in exercise capacity. These were real clinical endpoints, the things that matter to patients and their families, not just biomarkers or imaging findings.
The effect size was meaningful. Mortality was lower in the tafamidis group. Hospitalizations were fewer. Patients on tafamidis were walking longer distances on a six-minute walk test after thirty months than placebo patients, who had declined substantially. The drug works.
Tafamidis became the standard of care for ATTR cardiomyopathy from 2019 onward. Any patient diagnosed today is likely already on it. It slows the disease meaningfully. The ATTR-ACT trial showed real reductions in mortality and in hospitalizations. But it does not stop the disease entirely. Patients on tafamidis still accumulate amyloid over time. Heart function still declines, just more slowly. Many patients still experience progression. Some still die from cardiac causes during clinical trial follow-up.
The drug is real progress. It is not a cure.
The paper published this week in Nature Medicine tests a drug that attacks the problem from a completely different angle.
The drug is called eplontersen. It belongs to a class called antisense oligonucleotides. The name describes what they are: short synthetic strands of nucleic acid that are designed to interfere with the cell's own genetic messaging.
Here is how the cell normally makes transthyretin. The gene in the nucleus contains the instructions. When the liver needs transthyretin, the instructions are copied into a molecule called messenger RNA. Messenger RNA carries the instructions out of the nucleus to the protein-making machinery. The protein-making machinery reads the message and assembles the transthyretin protein.
Eplontersen is designed to intercept the messenger RNA. It is a short strand of nucleic acid engineered to match the sequence of the transthyretin messenger RNA. When eplontersen finds the messenger RNA, it binds to it. That binding flags the messenger RNA for destruction by the cell's own machinery. The message is gone before it can be read. The liver produces substantially less transthyretin protein.
The difference from tafamidis is fundamental. Tafamidis acts on the protein that has already been made: it stabilizes the cluster and prevents it from falling apart. Eplontersen acts upstream, at the messenger RNA level, before the protein ever exists. Tafamidis says: the boxes coming out of the factory sometimes arrive damaged and cause trouble, so we are going to reinforce them before they leave. Eplontersen says: let's just make fewer boxes.
The two mechanisms do not overlap. Tafamidis does nothing to the amount of transthyretin being made. Eplontersen does nothing to stabilize the clusters that do form. They target completely different steps in the same chain.
The question this paper asks is: what happens when you give eplontersen to a patient who is already on tafamidis?
Eplontersen was approved in late 2023 based on its efficacy in hereditary ATTR amyloidosis with neurological involvement. It is given by injection under the skin once a month. The once-monthly dosing matters for real-world adherence: tafamidis is a daily oral capsule, and adding a monthly injection is a different burden than adding another daily pill. In practice, patients who receive eplontersen go to their clinic once a month for the injection. The clinical infrastructure for this is building as the drug moves into wider use.
The antisense oligonucleotide class that eplontersen belongs to has established a track record over the past several years. Inclisiran is an RNA-silencing drug approved for high LDL cholesterol that works on the same general delivery principle. Patisiran and inotersen are earlier drugs in this class approved for hereditary TTR amyloidosis. The delivery mechanism, getting a synthetic nucleic acid strand specifically into liver cells after a subcutaneous injection, has been characterized and validated across multiple compounds and patients. Eplontersen is not a novel concept entering humans for the first time. It is a refined iteration on a platform with proven biology.
This is the clinical question that matters most right now. Tafamidis has been the standard of care since 2019. Every patient diagnosed today is already on it. If eplontersen is going to be used in real-world practice, it will almost always be added to existing tafamidis therapy, not given to a tafamidis-naive patient. Whether it works in that context is what cardiologists need to know.
The theoretical concern is that the two mechanisms might interact in a way that blunts the benefit of either. Tafamidis works by binding to and stabilizing the existing protein. Eplontersen reduces how much protein is made. Could reducing the total protein level interfere with tafamidis's ability to stabilize the protein that remains? Could they simply add together without interference? The answer is not obvious from theory alone.
The paper published in Nature Medicine is a secondary analysis of a phase three randomized controlled trial. The trial enrolled patients with ATTR cardiomyopathy and compared eplontersen against placebo. The secondary analysis looks at the results separately for two groups: patients who had no background transthyretin stabilizer when they enrolled, and patients who were already on a stabilizer, predominantly tafamidis.
The theoretical concern with combining two drugs that target the same protein through different mechanisms is real. Tafamidis stabilizes the transthyretin cluster by binding to it. If the total amount of transthyretin in the bloodstream is significantly reduced by eplontersen, does the reduction in target protein affect how well tafamidis can do its job? Does reducing TTR levels affect the concentration of tafamidis needed to maintain adequate stabilization? These are pharmacological questions that the trial results can address empirically even if the theory is uncertain.
The key finding: eplontersen showed efficacy in both groups. The drug worked in patients who were already on tafamidis. Background tafamidis did not blunt the response to eplontersen in this analysis.
The full text of this paper is behind a Nature Medicine paywall. I am working from the published abstract. I cannot give you the specific endpoint values, the exact magnitude of the effect in each subgroup, or the detailed safety profile. What the abstract reports is that eplontersen's effect was present with and without background stabilizer therapy.
Now for who is behind this paper.
The corresponding author is Pablo García-Pavía, a cardiologist based in Spain, as indicated by the contact email listed in the published metadata. García-Pavía is an established researcher in cardiac amyloidosis, with substantial publications on ATTR and light-chain amyloidosis diagnosis, staging, and treatment. He was the point of contact for the trial.
The senior, last-listed author is Mathew Maurer at Columbia University Irving Medical Center in New York. Maurer has been one of the leading American cardiologists in the ATTR amyloidosis field for over a decade. His group was involved in the recognition and clinical description of wild-type ATTR cardiomyopathy when it was still called senile cardiac amyloidosis, and he has contributed to multiple key clinical trials in the disease.
The author list includes cardiologists and amyloidosis specialists from the United Kingdom, Italy, Canada, Brazil, Sweden, Japan, and the United States, reflecting the international scope of the underlying trial.
Funding for this trial is not reported in the published abstract. Eplontersen was originally developed by Ionis Pharmaceuticals and is being commercialized by AstraZeneca, which completed an agreement to develop and commercialize eplontersen for ATTR amyloidosis. Given that context, industry involvement in funding trials of eplontersen is a reasonable expectation. But I cannot confirm the funding source from what I have. The paper's full funding and conflict of interest disclosures would tell you this directly, and if you are making clinical decisions based on this research, those disclosures are worth reading. If the trial was funded by the manufacturer of the drug being tested, that is information that belongs in your assessment of the result.
Now for what this secondary analysis can and cannot tell us, and how to hold the finding.
This is a secondary analysis. The original trial was powered and designed to answer a primary question about eplontersen's overall efficacy. The secondary analysis of the two subgroups, with and without background stabilizer, is a post-hoc question applied to the existing data. Secondary analyses have smaller effective sample sizes in each subgroup. The statistical thresholds and the interpretation are different. The result in the subgroup that included background tafamidis is an encouraging signal. It is not the same strength of evidence as a dedicated randomized trial designed from the beginning to test combination therapy directly.
The confirmatory question, whether eplontersen plus tafamidis is better than tafamidis alone in a prospective trial powered to detect a difference between those two specific regimens, would need its own trial to answer definitively.
There is also a biological consideration about what happens when you substantially reduce transthyretin levels over years. Transthyretin normally carries thyroid hormone and vitamin A in the blood. Reducing it is not without any theoretical consequence to those transport functions. The clinical trials of eplontersen and of similar drugs in this class have not shown significant adverse effects from transthyretin reduction at treatment doses, and the thyroid and retinol transport functions appear to have other mechanisms that compensate. But this is a biological reality worth monitoring over long follow-up periods, particularly in a patient population that may take the drug for many years.
What does this finding mean for someone living with ATTR cardiomyopathy right now?
If you are on tafamidis and your disease is stable and well-controlled, this paper does not necessarily mean you need to add eplontersen today. The question of whether and when to add a second drug depends on your disease trajectory, the specific form of ATTR you have, the access and cost considerations for eplontersen, and a conversation with a cardiologist who knows your specific situation.
If you are on tafamidis and your disease is progressing despite it, your cardiologist is likely already thinking about escalation. This paper gives them evidence that adding eplontersen to existing tafamidis therapy is not counterproductive and may provide additional benefit. That conversation is more supported by evidence today than it was before this publication.
If you have been diagnosed with ATTR cardiomyopathy but are not yet on any disease-modifying therapy, the standard of care since 2019 is to consider tafamidis, and this new data on eplontersen as an additional option would likely factor into the conversation about which approach fits your situation.
The larger picture is worth stepping back to see.
Transthyretin amyloid cardiomyopathy is a disease that was invisible for most of medical history. Found at autopsy. Not treated. Barely discussed. In the last decade, a nuclear imaging scan made it diagnosable without surgery. A randomized trial in 2019 showed that a drug could slow it. Now a paper in Nature Medicine shows that a second drug working through a completely different mechanism can be used alongside the first and still provides benefit.
This is the arc of a field catching up rapidly from a standing start. Diagnosis exists. A first treatment exists. Now there is evidence for a second treatment that stacks with the first.
The direction is toward combination therapy. That is the same trajectory as HIV, where three drugs targeting three different steps in the viral replication cycle became the standard because no single drug was sufficient. The same trajectory as hypertension, where blood pressure control typically requires multiple agents hitting different mechanisms. The same trajectory as multiple myeloma, where combination regimens have repeatedly outperformed single drugs. When a disease has multiple mechanisms contributing to its progression, blocking one of them partially addresses the problem. Blocking two different steps is potentially more effective.
There is a word that gets used a lot in discussions of ATTR cardiomyopathy that is worth examining: underdiagnosis. How underdiagnosed is the disease actually?
Estimates vary, but some analyses suggest that among people over seventy-five who die with unexplained heart failure, a significant fraction, numbers that have been estimated in some autopsy series at ten to twenty-five percent, have transthyretin amyloid deposits in their hearts. Most of those people were never diagnosed during their lives. They were treated for heart failure of unclear cause, received generic heart failure management, and died without anyone knowing what was actually causing the problem.
With the nuclear imaging scan available, cardiologists who know to order it can now identify the disease in living patients. But the knowledge of when to order that scan is not uniformly distributed. A cardiologist at a major academic medical center who has seen dozens of ATTR cardiomyopathy cases has a different index of suspicion than a community cardiologist who has seen one or two. The pattern recognition that triggers the diagnostic workup is still being distributed across the medical community, and that takes years.
ATTR cardiomyopathy is not cured by any combination of available treatments. The amyloid deposits already in the heart do not dissolve when you stop making new protein or when you stabilize the existing protein. What combination therapy aims to accomplish is slowing the accumulation of new deposits enough that the heart's function is better preserved over a longer period, potentially translating into more years of quality life before the disease progresses to the point of severe disability or death.
Whether combination therapy provides a survival benefit over tafamidis alone, reduces hospitalizations further, and maintains quality of life for longer, those are the questions that future dedicated trials will need to address. This paper tells us that the combination does not appear to be counterproductive and that the second drug still works in the presence of the first. That is the foundation the field needed before designing those larger trials.
It is worth returning for a moment to the diagnosis question, because it connects directly to who benefits from treatments like eplontersen.
If you have ATTR cardiomyopathy and do not know it, you are being treated for generic heart failure. The drugs you receive are chosen for heart failure of unclear cause, not specifically for amyloid. Some of those drugs are at best neutral in amyloid cardiomyopathy, and some are actually problematic. Digoxin, which is an older heart failure drug sometimes still used in certain patients, can actually bind to amyloid fibers in the heart and worsen toxicity. Beta blockers, which are commonly used in systolic heart failure, can be poorly tolerated in ATTR cardiomyopathy because of the specific physiology of the stiff heart. The right diagnosis is not just about getting access to a specific treatment. It is about being protected from the wrong ones.
The nuclear imaging scan that makes non-invasive diagnosis possible, the technetium pyrophosphate scan, is not widely available everywhere. It requires a nuclear medicine department with the tracer and the expertise to interpret the scan in the context of amyloid. In academic medical centers and large hospitals, this is available. In community settings, especially in countries with less developed nuclear medicine infrastructure, it may not be. The diagnosis gap is therefore partly a knowledge gap and partly an access gap.
The cost dimension of combination therapy is also real. Tafamidis is one of the most expensive drugs in cardiology: the list price in the United States has been over two hundred thousand dollars per year. Eplontersen is also an expensive drug. Combination therapy with both would add up to a very high annual cost per patient. Health technology assessment bodies in different countries evaluate cost-effectiveness, comparing the cost of the treatment to the benefit in terms of years of quality life gained. At current prices, combination ATTR therapy will face scrutiny in any health system that has to decide whether to cover it.
Whether the prices come down over time, whether generic competition enters the market for tafamidis as patents expire, and how payers respond to the evidence from combination trials, all of that affects who actually benefits from these advances in practice. The science moving forward and the economics keeping treatments accessible are two separate problems, and history suggests the second is harder to solve.
Where does this leave someone with ATTR cardiomyopathy today?
The combination of tafamidis with eplontersen, if it becomes the standard of care based on trials like this one and subsequent dedicated studies, would likely involve a daily pill and a monthly injection. That is a moderate burden. The monthly clinic visit for the injection adds a touch point with the healthcare system that has its own value: the clinician sees the patient monthly, can track symptoms, adjust other medications, and catch deterioration early.
Whether the combination becomes a formal guideline recommendation depends on regulatory reviews, on whether health technology assessment bodies in different countries find the cost-effectiveness acceptable, and on whether additional data from dedicated combination trials further strengthens the case. Guidelines in cardiology move slowly and deliberatively. The Nature Medicine paper is one piece of the evidence base. The cardiologists on guideline committees will wait for several pieces before recommending a formal change in standard practice.
The broader story of ATTR cardiomyopathy over the last decade is one of a field catching up very fast from a standing start. The disease was found mostly at autopsy. Then imaging made it diagnosable. Then tafamidis showed it was treatable. Now eplontersen shows a second mechanism can be added. That arc from invisible to diagnosable to treatable to combinable is the arc of modern medical progress in a disease area that most of the people who had the disease never knew had a name.
The people who have the disease now, diagnosed and on treatment, are benefiting from that acceleration. The people who had it twenty years ago, when there was no treatment and no diagnosis, were mostly buried without their doctors knowing what caused their heart failure.
That contrast is not unique to ATTR cardiomyopathy. It appears in many diseases. The timing of being born determines what treatments exist when you get sick. For ATTR cardiomyopathy, the timing has dramatically improved in a very short period of time.
The paper is PMID 42742182, published in Nature Medicine on August 30, 2026. This is based on the published abstract; the full text is behind a paywall.